Your browser doesn't support javascript.
loading
[Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation].
Liu, J; Lyu, M; Zhang, Y Y; Mo, X D; Sun, Y Q; Yan, C H; Wang, Y; Xu, L P; Zhang, X H; Liu, K Y; Huang, X J.
Afiliación
  • Liu J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Lyu M; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Zhang YY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Sun YQ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Yan CH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
Zhonghua Xue Ye Xue Za Zhi ; 45(6): 542-548, 2024 Jun 14.
Article en Zh | MEDLINE | ID: mdl-39134484
ABSTRACT

Objective:

To analyze the causes and demographic characteristics of pre-engraftment mortality in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and investigate the risk factors and measures for preventing pre-engraftment mortality.

Methods:

A retrospective case analysis, involving a total of 7 427 patients who underwent allo-HSCT at Peking University People's Hospital between January 2016 and July 2023, was conducted.

Results:

Among the 7 427 patients who underwent allo-HSCT, 56 cases (0.75% ) experienced pre-engraftment mortality. The median time to death for these 56 patients was +7 (-3 to +38) days after stem cell infusion. The median times to death for patients with acute leukemia (AL), severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS) were +11 (-1 to +38), +3 (-1 to +34), and +16 (-1 to +38) days, respectively (P=0.013). The main causes of pre-engraftment mortality were infection (39.3% ), cardiac toxicity (28.6% ), and intracranial hemorrhage (26.8% ). Infection was the most common cause of pre-engraftment mortality in patients with AL and MDS (55.0% and 60.0% ), whereas cardiac toxicity was predominantly observed in patients with SAA (71.4% ), with no cases in patients with AL and only one case in patients with MDS. Among patients who died from intracranial hemorrhage, 53.3% had severe infections. The median times to death for infection, cardiac toxicity, and intracranial hemorrhage was +11 (-1 to +38), +2.5 (-1 to +17), and +8 (-3 to +37) days, respectively (P<0.001) .

Conclusions:

Infection is the primary cause of pre-engraftment mortality in allo-HSCT, and severe cardiac toxicity leading to pre-engraftment mortality should be closely monitored in patients with SAA.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante Homólogo / Trasplante de Células Madre Hematopoyéticas Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante Homólogo / Trasplante de Células Madre Hematopoyéticas Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2024 Tipo del documento: Article